The publisher forecasts that by 2030, the global epilepsy drugs market is expected to approach approximately US$ 10.28 billion. Epilepsy drugs play a giant function in the healthcare zone worldwide because of the substantial occurrence of epilepsy, impacting a giant quantity of people. The persistent demand for these medicines is driven by the necessity to correctly manipulate and control seizures. Additionally, ongoing advancements in drug improvement and remedy techniques always enlarge the options available to sufferers and healthcare companies. This popularity underscores the essential role of epilepsy drugs in enhancing patient outcomes and enhancing the satisfaction of lifestyles for those affected by epilepsy.
Further, innovative drug formulations like extended-release drugs and novel drug delivery methods are improving the variety of treatment options available for epilepsy patients. These new improvements in drug delivery technology assist in addressing demanding situations like dosing frequency and fluctuating blood levels, ultimately leading to higher patient effects. Matching treatment techniques to precise epilepsy kinds and individual patient necessities increases the need for a wide range of medications, supporting the development of the global epilepsy drugs market. The market strives to satisfy the evolving needs of patients worldwide by providing numerous medicine options to enhance patient compliance and treatment efficacy.
Also, the significant market percentage for epilepsy drugs may be in North America. This is because of a boom in neurological problems like Parkinson's ailment, along with multiplied focus and tremendous research outcomes. The US invests in growing new epilepsy drugs, enhancing the general marketplace. According to the Parkinson's Foundation, 930,000 humans within the US have Parkinson's ailment, and this is anticipated to develop to 1.2 million by 2030. The Asia-Pacific region is also increasing and is estimated to have the fastest expansion because of the large population there. Epilepsy is a significant healthcare challenge in that place because of the wide variety of people affected by it. Hence, the global epilepsy drugs market was valued at US$ 7.62 Billion in 2023.
In January 2023 - Zydus Lifesciences established Topiramate extended-release capsules, a generic medication for treating epilepsy in the United States market.
In March 2022 - Lupin's abbreviated new Vigabatrin application (ANDA), an antiepileptic drug available as an oral solution USP (500 mg), received approval from the United States Food and Drug Administration.
2. Second Generation Drugs
3. Third Generation Drugs
2. Generalized Seizures
3. Non-Epileptic Seizures
2. Drug Stores and Retail Pharmacies
3. Online Providers
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
6. Rest of the World
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
5. Abbott Laboratories
6. Alkem Laboratories Limited
7. Bausch Health Companies Inc.
8. GSK plc
9. Novartis AG.
10. Pfizer Inc.
Between 2024 and 2030, the global epilepsy drugs market is predicted to develop at a compound annual growth rate (CAGR) of 4.37%
The World Health Organization (WHO) states that, epilepsy ranks among the most common neurological conditions worldwide, impacting an estimated 50 million individuals. The marketplace is witnessing boom propelled by the advent of recent and stepped forward medicinal drugs, offering additional remedy alternatives. Addressing the evolving wishes of individuals with epilepsy through advanced pharmaceutical interventions will become essential, given the interplay of these factors.Further, innovative drug formulations like extended-release drugs and novel drug delivery methods are improving the variety of treatment options available for epilepsy patients. These new improvements in drug delivery technology assist in addressing demanding situations like dosing frequency and fluctuating blood levels, ultimately leading to higher patient effects. Matching treatment techniques to precise epilepsy kinds and individual patient necessities increases the need for a wide range of medications, supporting the development of the global epilepsy drugs market. The market strives to satisfy the evolving needs of patients worldwide by providing numerous medicine options to enhance patient compliance and treatment efficacy.
Also, the significant market percentage for epilepsy drugs may be in North America. This is because of a boom in neurological problems like Parkinson's ailment, along with multiplied focus and tremendous research outcomes. The US invests in growing new epilepsy drugs, enhancing the general marketplace. According to the Parkinson's Foundation, 930,000 humans within the US have Parkinson's ailment, and this is anticipated to develop to 1.2 million by 2030. The Asia-Pacific region is also increasing and is estimated to have the fastest expansion because of the large population there. Epilepsy is a significant healthcare challenge in that place because of the wide variety of people affected by it. Hence, the global epilepsy drugs market was valued at US$ 7.62 Billion in 2023.
The epilepsy drugs market has a significant share of the second-generation drug category
By drug category, the global epilepsy drugs market is fragmented into First Generation Drugs, Second Generation Drugs, and Third Generation Drugs. The phase of second-generation medicinal drugs held a sizeable portion of the epilepsy drugs market, largely because of their focused method of addressing various sorts of seizures with decreased side effects. Additionally, they offer broader applicability and a lower danger of drug interactions. Referred to as more modern AEDs (antiepileptic drugs), second-generation medicines constitute an extra modern-day class of antiepileptic treatments developed through researchers to improve efficacy, tolerability, and protection compared to their predecessors. Examples consist of levetiracetam, lamotrigine, and topiramate.Focal seizures command a prominent share in the global epilepsy drugs market
By seizure types, the global epilepsy drugs market is segmented into Focal Seizures, Generalized Seizures, and Non-Epileptic Seizures. Focal seizures are anticipated to be among the most remarkable portions of the global epilepsy drugs market. This is because of their vast occurrence and diverse manifestations. As one of the most common seizure types, focal seizures affect a massive number of epilepsy sufferers across the world. Their numerous presentations, from subtle to severe, necessitate diverse remedy alternatives, pivoting the call for pharmaceutical interventions. Companies prioritize studies and development of drugs tailored to address the particular needs of individuals experiencing focal seizures, solidifying their prominence inside the epilepsy drugs market.The drug stores and retail pharmacies segment had one of the highest shares in the global epilepsy drugs market
By distribution channels, the global epilepsy drugs market is categorized into hospital pharmacies, drug stores, retail pharmacies, and online providers. The drug stores and retail pharmacies section stands out as having one of the most substantial shares within the international epilepsy tablets market. This is driven by the extensive accessibility of these outlets, imparting convenient access to a wide variety of antiepileptic medicines. Patients frequently rely upon these institutions for routine prescription refills and pharmacist consultations, contributing drastically to the section's market percentage. Drug shops and retail pharmacies' convenience, availability, and information solidify their pivotal function in distributing epilepsy drugs worldwide.United States has the lion's share of the global epilepsy drugs market
By countries, the global epilepsy drugs market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), Latin America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, United Arab Emirates), and Rest of the World. The United States is projected to experience a substantial increase in the market for epilepsy drugs. This is because of the increasing burden of epilepsy and the market players' strategic projects, focus campaigns, and the launch of the latest products. According to a press release of the CDC in 2022, around 3.4 million Americans have epilepsy, and about 1 in 10 people may additionally experience a seizure throughout their lifetime. The United States has over 260 epilepsy centers, wherein healthcare vendors concentrate on dealing with epilepsy and offering professional care to kids and adults. As a result, the prevalence of epilepsy within the area is predicted to force the demand for its remedy, leading to an expanded market increase.Key Players
Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc., Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., GSK plc, Novartis AG., and Pfizer Inc. are the businesses in the global epilepsy drugs market.In January 2023 - Zydus Lifesciences established Topiramate extended-release capsules, a generic medication for treating epilepsy in the United States market.
In March 2022 - Lupin's abbreviated new Vigabatrin application (ANDA), an antiepileptic drug available as an oral solution USP (500 mg), received approval from the United States Food and Drug Administration.
Drug Category - Market breakup in 4 viewpoints:
1. First Generation Drugs2. Second Generation Drugs
3. Third Generation Drugs
Seizure Types - Market breakup in 3 viewpoints:
1. Focal Seizures2. Generalized Seizures
3. Non-Epileptic Seizures
Distribution Channel - Market breakup in 3 viewpoints:
1. Hospital Pharmacies2. Drug Stores and Retail Pharmacies
3. Online Providers
Countries - Market breakup in 26 viewpoints:
1. North America1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
6. Rest of the World
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Eisai Co., Ltd.2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
5. Abbott Laboratories
6. Alkem Laboratories Limited
7. Bausch Health Companies Inc.
8. GSK plc
9. Novartis AG.
10. Pfizer Inc.
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary6. Global Epilepsy Drugs Market16. Regulations and Reimbursement Policies
4. Market Dynamics
5. Exploring the Disease - Background and Key Insights
7. Market Share - Global Epilepsy Drugs Market
8. Drugs Category - Global Epilepsy Drugs Market
9. Seizure Types - Global Epilepsy Drugs Market
10. Distribution Channels - Global Epilepsy Drugs Market
11. Countries - Global Epilepsy Drugs Market
12. Porter’s Five Forces Analysis - Global Epilepsy Drugs Market
13. SWOT Analysis - Global Epilepsy Drugs Market
14. Analysis of Marketed Medications/Drugs
15. Analysis of Emerging Drugs
17. Key Players Analysis
List of Figure
List of Tables
Companies Mentioned
- Eisai Co., Ltd.
- UCB Inc.
- H. Lundbeck A/S
- GW Pharmaceuticals Plc.
- Abbott Laboratories
- Alkem Laboratories Limited
- Bausch Health Companies Inc.
- GSK plc
- Novartis AG.
- Pfizer Inc."
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 7.62 Billion |
| Forecasted Market Value ( USD | $ 10.28 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
